Clinical trials: Stage IV Renal Cell Cancer
Solid Tumors
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety, tolerability, pharmacokinetics and preliminary efficacy of ABBV-303 as a monotherapy…
- Trial name
- NCT06158958
- Testing
- ABBV-303, Budigalimab
- Where
- 18 sites in United States, Israel and 1 more
- Volunteers
- 27 people
- Sponsor
- AbbVie
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer
Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer
A Phase I/II study of an in-situ therapeutic cancer vaccine. Vaccines contain a source of antigen and and adjuvant. In this study the source of tumor antigen comes from the killing of a selected tumor by cryoablation (killing…
- Conditions
- Solid Tumors Stage II, Stage III and Stage IV, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT01065441
- Testing
- AlloStim, Cryoablation
- Where
- Israel
- Volunteers
- 9 people
- Sponsor
- Michael Har-Noy
Renal Angiomyolipoma
A Phase IV Study of Safety and Efficacy of Everolimus in Taiwanese Patients With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma (TSC-AML)
The purpose of this prospective study is to assess the safety and efficacy of everolimus in Taiwanese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC) .
- Trial name
- NCT05252585
- Testing
- Everolimus
- Where
- 4 sites in Taiwan
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Stage IV Renal Cell Carcinoma
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Single-center, open label, non-randomized, fixed dose-escalation, phase 1 study, performed in ambulatory and day-hospital setting
- Trial name
- NCT00351949
- Testing
- IMP321
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Immutep S.A.S.
Carcinoma, Renal Cell
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
CPG 7909 given alone to patients with renal cell cancer after their nephrectomy. CPG 7909 is as a subcutaneous injection once per week for up to 24 weeks. Up to 40 patients will be included in the study.
- Trial name
- NCT00043407
- Testing
- CPG 7909
- Volunteers
- 42 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma
This is a two arm, open-label, dose escalation and dose expansion clinical study to evaluate the safety and efficacy of infusion of autologous CCT301-38 or CCT 301-59 T cells in adult subjects with relapsed and refractory stage…
- Trial name
- NCT03393936
- Testing
- CCT301-38, CCT301-59
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Renal Cell Carcinoma
Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer
The purpose of this trial is to examine the safety, feasibility, immunological response, and clinical antitumor activity of multiple administrations of dendritic cell Immunotherapeutic to patients with newly diagnosed with…
- Trial name
- NCT00272649
- Testing
- AGS-003
- Where
- 10 sites in United States, Canada
- Volunteers
- 22 people
- Sponsor
- Argos Therapeutics
Renal Cell Carcinoma, Nasopharyngeal Carcinoma
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Brief Summary: This study will test the safety, including side effects, and determine the characteristics of a drug called GEN1160 (PRO1160) in participants with solid tumors and blood cancers.
- Conditions
- Renal Cell Carcinoma, Nasopharyngeal Carcinoma, Non Hodgkin Lymphoma
- Trial name
- NCT05721222
- Testing
- GEN1160
- Where
- 17 sites in United States, China
- Volunteers
- 42 people
- Sponsor
- Genmab
Kidney Cancer
BAY 59-8862 in Treating Patients With Advanced Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have advanced…
- Trial name
- NCT00039169
- Testing
- ortataxel
- Where
- 13 sites in United States, Canada
- Sponsor
- Theradex
Gastric Adenocarcinoma, Esophageal Cancer
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
The primary objective in Phase I is to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent administered in 21-day treatment cycles in previously treated participants with advanced epithelial…
- Conditions
- Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT01631552
- Testing
- Sacituzumab Govitecan-hziy (SG)
- Where
- 12 sites in United States
- Volunteers
- 515 people
- Sponsor
- Gilead Sciences
Metastatic Renal Cell Carcinoma
A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer
The primary objective of this study is to answer the question "Is it possible to inject the Combig-DC vaccine in a renal tumour without getting unacceptable side effects"? Patients newly diagnosed with metastatic renal cell…
- Trial name
- NCT01525017
- Testing
- Combig-DC (allogeneic dendritic cells) Cancer Vaccine
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Mendus
Transitional Cell Carcinoma, Bladder Neoplasms
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
The purpose of this clinical research study is to learn if vinflunine can shrink or slow the growth of the cancer or increase survival in patients with transitional cell carcinoma of the urothelium.
- Conditions
- Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms
- Trial name
- NCT00101608
- Testing
- vinflunine
- Where
- 75 sites in United States, Australia and 13 more
- Volunteers
- 150 people
- Sponsor
- Bristol-Myers Squibb
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
Kidney Cancer
AE-941 in Treating Patients With Metastatic Kidney Cancer
RATIONALE: AE-941 may stop the growth of kidney cancer by stopping blood flow to the tumor. PURPOSE: Randomized phase III trial to determine the effectiveness of AE-941 in treating patients who have metastatic kidney cancer that…
- Trial name
- NCT00005995
- Testing
- shark cartilage extract AE-941
- Where
- Canada
- Sponsor
- AEterna Zentaris
Kidney Cancer
Vaccine Therapy in Treating Patients With Kidney Cancer
RATIONALE: Vaccines made from a patient's white blood cells and tumor cells may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00014131
- Testing
- Biological/Vaccine: therapeutic autologous dendritic cells.
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Lisata Therapeutics, Inc.
Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer
A Study of VET3-TGI in Patients With Solid Tumors
VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by…
- Conditions
- Solid Tumor, Adult, Microsatellite Stable Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer
- Trial name
- STEALTH-001 (NCT06444815)
- Testing
- VET3-TGI, Atezolizumab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- KaliVir Immunotherapeutics
Breast Cancer, Kidney Cancer
Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer
RATIONALE: Interleukin-4 PE38KDEL cytotoxin may be able to deliver cancer-killing substances directly to solid tumor cells. PURPOSE: Phase I trial to study the effectiveness of intravenous interleukin-4 PE38KDEL cytotoxin in…
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00039052
- Testing
- interleukin-4 PE38KDEL cytotoxin
- Where
- 2 sites in United States
- Sponsor
- Neurocrine Biosciences
Cancer, Renal Cell Carcinoma
Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients
This phase 1/2a trial is conducted in Europe. The first part of the trial is a dose escalation safety trial determining the maximum tolerated dose of rIL-21 when administered in combination with sunitinib.
- Trial name
- NCT00617253
- Testing
- recombinant interleukin-21, sunitinib
- Where
- 5 sites in Germany, Netherlands
- Volunteers
- 9 people
- Sponsor
- Novo Nordisk A/S
Kidney Cancer
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00087022
- Testing
- girentuximab
- Where
- 56 sites in United States, Argentina and 2 more
- Volunteers
- 864 people
- Sponsor
- Heidelberg Pharma AG